SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning
Standard
SURMOUNT-2 : new advances for treating obese type 2 diabetes with tirzepatide. / Frandsen, Christian Seerup; Madsbad, Sten.
I: The Lancet, Bind 402, Nr. 10402, 2023, s. 586-588.Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning
Harvard
Frandsen, CS & Madsbad, S 2023, 'SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide', The Lancet, bind 402, nr. 10402, s. 586-588. https://doi.org/10.1016/S0140-6736(23)01292-8
APA
Frandsen, C. S., & Madsbad, S. (2023). SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide. The Lancet, 402(10402), 586-588. https://doi.org/10.1016/S0140-6736(23)01292-8
Vancouver
Frandsen CS, Madsbad S. SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide. The Lancet. 2023;402(10402):586-588. https://doi.org/10.1016/S0140-6736(23)01292-8
Author
Bibtex
@article{298f1a4fa5604b9eaf6b81927b07a1c9,
title = "SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide",
author = "Frandsen, {Christian Seerup} and Sten Madsbad",
year = "2023",
doi = "10.1016/S0140-6736(23)01292-8",
language = "English",
volume = "402",
pages = "586--588",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "10402",
}
RIS
TY - JOUR
T1 - SURMOUNT-2
T2 - new advances for treating obese type 2 diabetes with tirzepatide
AU - Frandsen, Christian Seerup
AU - Madsbad, Sten
PY - 2023
Y1 - 2023
U2 - 10.1016/S0140-6736(23)01292-8
DO - 10.1016/S0140-6736(23)01292-8
M3 - Comment/debate
C2 - 37385274
AN - SCOPUS:85163518327
VL - 402
SP - 586
EP - 588
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10402
ER -
ID: 397248329